Dutch feed giant Nutreco invested in Israeli startup ViAqua as part of its focus on combatting disease in the aquaculture industry, it announced Wednesday.

ViAqua is developing the first orally-administered treatment for shrimp that improves resistance to viral diseases, including White Spot Syndrome Virus (WSSV), and prevents viral epidemics.

Nutreco said it has taken "a meaningful minority share that will conditionally grow over time."

The solution offered by ViAqua, which was founded in 2014, uses a proprietary particle to disable viral infections.